A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N03261
      QxMD      Google Scholar   
Citation:
Cancer vol 116 (24) 5686-5693
Year:
2010
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
SDC:
No
Book Volume:
Parents:
398  
Children:
None
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
   
Pharmas:
 
Grants:
CA-37, 404, U10 CA052352, CA-37, 417, CA-63, 848, U10 CA037417, CA-25, 224, CA-35, 195, U10 CA037404, U10 CA063848, U10 CA035195, 101, U10 CA035101, U10 CA035113, U10 CA035415, 415, CA-52, 352, U10 CA025224, 103, 113, U10 CA035103  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
N0326
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Article